PL356745A1 - Inhibitory przyrostu wagi ciała - Google Patents

Inhibitory przyrostu wagi ciała

Info

Publication number
PL356745A1
PL356745A1 PL00356745A PL35674500A PL356745A1 PL 356745 A1 PL356745 A1 PL 356745A1 PL 00356745 A PL00356745 A PL 00356745A PL 35674500 A PL35674500 A PL 35674500A PL 356745 A1 PL356745 A1 PL 356745A1
Authority
PL
Poland
Prior art keywords
body weight
weight gain
inhibitors
gain inhibitors
weight
Prior art date
Application number
PL00356745A
Other languages
English (en)
Inventor
Yasuo Sugiyama
Hiroyuki Odaka
Hiroyuki Kimura
Original Assignee
Takeda Chemical Industries, Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries, Ltd filed Critical Takeda Chemical Industries, Ltd
Publication of PL356745A1 publication Critical patent/PL356745A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL00356745A 1999-11-10 2000-11-09 Inhibitory przyrostu wagi ciała PL356745A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP32031999 1999-11-10

Publications (1)

Publication Number Publication Date
PL356745A1 true PL356745A1 (pl) 2004-06-28

Family

ID=18120170

Family Applications (1)

Application Number Title Priority Date Filing Date
PL00356745A PL356745A1 (pl) 1999-11-10 2000-11-09 Inhibitory przyrostu wagi ciała

Country Status (10)

Country Link
US (1) US20050239854A1 (pl)
EP (1) EP1304121A4 (pl)
KR (1) KR20020060227A (pl)
CN (1) CN1423566A (pl)
AU (1) AU1303301A (pl)
CA (1) CA2390932A1 (pl)
HU (1) HUP0203837A2 (pl)
NO (1) NO20022214L (pl)
PL (1) PL356745A1 (pl)
WO (1) WO2001034200A1 (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1229026A4 (en) * 1999-11-10 2003-09-24 Takeda Chemical Industries Ltd ALCOXYIMINOALKANOIC ACID DERIVATIVES
EP1277730A4 (en) * 2000-03-28 2005-03-16 HEMMER OF NEOVASCULARIZATION
EP1357914A2 (en) * 2001-02-02 2003-11-05 SmithKline Beecham Corporation Treatment of ppar mediated diseases
ATE480236T1 (de) * 2001-04-25 2010-09-15 Takeda Pharmaceutical Verwendung des abc-expressionspromotors pioglitazon zur behandlung von arteriosklerose obliterans
JP2005501058A (ja) 2001-07-31 2005-01-13 ザ ガバメント オブ ザ ユナイテッドステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ ザ ナショナル インステ Ｇｌｐ−１、ｅｘｅｎｄｉｎ−４、そのペプチド・アナログ及びその使用
AU2003220855A1 (en) * 2002-04-01 2003-10-13 Sankyo Company, Limited Medicinal antitumor composition
ATE551056T1 (de) 2002-12-27 2012-04-15 Takeda Pharmaceutical Mittel zur hemmung der körpergewichtszunahme
JP2007536343A (ja) 2004-05-05 2007-12-13 ノボ　ノルディスク　アクティーゼルスカブ Ｐｐａｒアゴニストとしてのフェノキシ酢酸誘導体
EP1745014B1 (en) 2004-05-05 2011-07-06 High Point Pharmaceuticals, LLC Novel compounds, their preparation and use
US7943669B2 (en) 2005-06-30 2011-05-17 High Point Pharmaceuticals, Llc Phenoxy acetic acids as PPAR delta activators
US8097610B2 (en) * 2005-08-26 2012-01-17 Shionogi & Co., Ltd. Derivative having PPAR agonistic activity
EA201101084A1 (ru) 2005-12-22 2012-04-30 ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Феноксиуксусные кислоты в качестве активаторов ppar дельта
JP2009529512A (ja) 2006-03-09 2009-08-20 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー 新規な化合物、それらの製造法、及び使用法
WO2010011302A1 (en) * 2008-07-22 2010-01-28 Chdi, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
JP2014502252A (ja) 2010-09-28 2014-01-30 アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー 作用持続時間が増した改変ポリペプチド
BR112014004741B1 (pt) 2011-08-30 2021-10-13 Chdi Foundation, Inc Entidade química, seu uso e composição farmacêutica compreendendo a mesma
AU2012300246A1 (en) 2011-08-30 2014-03-06 Chdi Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
ES2811087T3 (es) 2013-09-09 2021-03-10 Vtv Therapeutics Llc Uso de agonistas de PPAR-delta para tratar la atrofia muscular
AU2015289492B2 (en) 2014-07-17 2020-02-20 Chdi Foundation, Inc. Methods and compositions for treating HIV-related disorders
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5512581A (en) * 1994-07-18 1996-04-30 Abbott Laboratories Iminoxycarboxylates and derivatives as inhibitors of leukotriene biosynthesis
GB9606805D0 (en) * 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
ES2320181T3 (es) * 1997-07-24 2009-05-19 Astellas Pharma Inc. Composiciones farmaceuticas que tienen un efecto reductor del colesterol.
AU740733B2 (en) * 1997-12-19 2001-11-15 Merck & Co., Inc. Arylthiazolidinedione derivatives
MY123337A (en) * 1998-05-11 2006-05-31 Takeda Chemical Industries Ltd Oxyiminoalkanoic acid derivatives.
TWI249401B (en) * 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
WO2001032608A1 (en) * 1999-10-29 2001-05-10 Takeda Chemical Industries, Ltd. Process for the preparation of oxyiminoalkanoic acid derivatives

Also Published As

Publication number Publication date
WO2001034200A1 (en) 2001-05-17
AU1303301A (en) 2001-06-06
NO20022214L (no) 2002-07-09
KR20020060227A (ko) 2002-07-16
HUP0203837A2 (hu) 2003-03-28
US20050239854A1 (en) 2005-10-27
EP1304121A1 (en) 2003-04-23
NO20022214D0 (no) 2002-05-08
CN1423566A (zh) 2003-06-11
CA2390932A1 (en) 2001-05-17
EP1304121A4 (en) 2004-06-23

Similar Documents

Publication Publication Date Title
GB9926956D0 (en) Amplifier
EG23817A (en) 4-Phenyl-pyridine derivatives
IL145836A0 (en) Substituted azoles
GB9900416D0 (en) Inhibitors
GC0000183A (en) 3-Phenyl-pyridine derivatives
AU1303301A (en) Body weight gain inhibitors
HU0002792D0 (en) Triazole and imidazole derivatives
GC0000338A (en) 5-Phenyl-pyrimidine derivatives
GB9928355D0 (en) Amplifier
GB2351063B (en) Load carrying body
SI1154988T1 (en) Mevinolin derivatives
GC0000191A (en) 4-Phenyl-pyrimidine derivatives
GB9913548D0 (en) Amplifier
EP1153022A4 (en) PROTEASE INHIBITORS
GC0000256A (en) Ethanesulfonyl-piperidine derivatives
GB9925880D0 (en) B-Carboline derivatives
AP2001002327A0 (en) 1-Trifluoromethyl-4-hydroxy-7- piperidinylaminomethy lchroman derivatives
EP1459755A4 (en) BODY WEIGHT TAKING INHIBITOR
HU0003555D0 (en) Triazole derivatives having antifugal activity
GB9900032D0 (en) Amplifier
AU141197S (en) Plough body
CA88366S (en) Cereal piece
CA88367S (en) Cereal piece
GB9911252D0 (en) Weight
GB9904754D0 (en) Body protection

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)